



# Application of directed metallation in synthesis: total synthesis of model compounds related to semivioxanthin



Sukanta Kamila, Chandrani Mukherjee and Asish De\*

Department of Organic Chemistry, Indian Association for the Cultivation of Science, Jadavpur, Kolkata 700 032, India

Received 1 May 2001; accepted 28 June 2001

**Abstract**—Two model compounds related to the naturally occurring antifungal compound semivioxanthin were synthesized from readily available starting materials using a directed metallation–transmetallation–allylation–cyclization protocol. © 2001 Elsevier Science Ltd. All rights reserved.

The undiminished importance of heteroatom directed *ortho* metallation<sup>1</sup> as an effective tool in synthetic aromatic chemistry is corroborated by its continuing use in regioselective functionalisation of aromatic or heteroaromatic nuclei and the subsequent utilization of the introduced functionalities for annelation purposes. We report here the application of this methodology for the synthesis of two model compounds **1** and **2** related to the naturally occurring antifungal compound semivioxanthin<sup>2</sup> (**3**), from commercially available or easily accessible starting materials.



Semivioxanthin was earlier synthesized via long routes<sup>3</sup> or using toxic chemicals.<sup>4</sup> The directed metallation–transmetallation–allylation–cyclization protocol utilised


here is an attractive alternative because it involves only a few steps and can be equally adopted to synthesize the natural product or analogues.

The synthesis of 2,3-dihydro-2-methyl-5,9-dimethoxy naphtho[7,6-*c*]pyran 10-one (**1**) from commercially available 1,5-dihydroxynaphthalene is shown in Scheme 1.<sup>5</sup>

The two hydroxyl functions of **4** were converted sequentially into methoxy and *O*-carbamate groups and the resulting compound **6** was deprotonated in the position *ortho* to the *O*-carbamate under standard directed metallation conditions.<sup>1</sup> When kept at room temperature for 16 h, the deprotonated species underwent an anionic Fries rearrangement<sup>6</sup> and the resulting salicylamide was methylated without further purification to afford **7** in a 35% overall yield. Attempts to introduce an allyl group *ortho* to the CONEt<sub>2</sub> function via metallation–transmetallation<sup>7</sup> were unsuccessful. An examination of the NMR of the reaction product suggested that demethylation of the methoxy group *ortho* to CONEt<sub>2</sub> was followed by formation of the *O*-allylated product among others, leading to an intractable mixture. This problem was circumvented by introducing a CONEt<sub>2</sub> function *ortho* to the *O*-carbamate by deprotonation and quenching with *N,N*-diethyl carbamoyl chloride affording **8**. Allylation *ortho* to the CONEt<sub>2</sub> in **8** was achieved in high yield by lithiation, transmetallation with CuBr–SMe<sub>2</sub><sup>8</sup> and quenching with allyl bromide. The resulting compound **9** was cyclized by heating with 6N HCl for 36 h. The *O*-carbamate function was hydrolyzed during the cyclization as corroborated by the disappearance of the carbonyl peak at 1708 cm<sup>-1</sup> in the IR of the cyclized product and the

**Keywords:** semivioxanthin; directed metallation; transmetallation.


\* Corresponding author: Tel.: +(91)(33) 473 4971 ext. 246/253. Fax: +(91)(33) 473-2805; e-mail: ocad@mahendra.iacs.res.in



**Scheme 1.** Reagents and conditions: (i)  $K_2CO_3$ /acetone; (ii) MeI; (iii)  $CICONET_2/NaH/THF$ ; (iv) *sec*-BuLi (2.5 equiv.)/TMEDA/ $-78^\circ C$  to rt, 12 h; (v) *sec*-BuLi (2.5 equiv.) TMEDA/THF/ $-78^\circ C$ ; (vi)  $CICONET_2$ ; (vii)  $CuBr-Me_2S$ , allyl bromide; (viii) 6N HCl/ $\Delta$ /36 h.

appearance of a peak due to the hydroxyl function at  $3323\text{ cm}^{-1}$ . The crude product was methylated ( $K_2CO_3$ -acetone-MeI) to afford **1** in a 61% overall yield.

The model compound 2,3-dihydro-2-methyl-4-methoxy-[1]benzothieno[2,3-*c*]pyran 9-one (**2**) was synthesized from 4-methoxy benzo[*b*]thiophene(**10**)<sup>9</sup> (Scheme 2).



**Scheme 2.** Reagents and conditions: (i) *n*-BuLi (1.2 equiv.)/THF/ $-78^\circ C$ /THF, rt, 16 h; (ii) *n*-BuLi (1.1 equiv.)/THF/ $-78^\circ C$ / $CICONET_2$ / $-78^\circ C$ -rt/16 h; (iii) *sec*-BuLi (2.5 equiv.)/THF/ $CuBr-Me_2S$ / $-78$  to  $-30^\circ C$ ; (iv) allyl bromide/ $-78^\circ C$ ; (v) 6N HCl reflux for 60 h.

Introduction of the CONEt<sub>2</sub> functionality at the 2-position in **10** was achieved by deprotonation with *n*-BuLi followed by quenching with *N,N*-diethyl carbamoyl chloride. Introduction of the allyl function *ortho* to the CONEt<sub>2</sub> and cyclization was carried out by the usual metallation–transmetallation process.

The construction of the linear tricyclic skeleton carrying oxygenated functions present in semivioxanthin in reasonably good yields is thus achievable by this methodology. Work is in progress on the total synthesis of the natural product and other analogues which will be reported later.

### Acknowledgements

Thanks are due to the Council of Scientific and Industrial Research (New Delhi) for a grant, the Bose Institute (Calcutta) for 500 MHz NMR spectra and Dr. Ganesh Pandey for a generous gift of *sec*-butyllithium.

### References

1. Snieckus, V. *Chem. Rev.* **1990**, *90*, 879.
2. Zeeck, A.; Russ, P.; Laotsch, H.; Loeffler, W.; Wehrde, H.; Zahner, H.; Holst, H. *Chem. Ber.* **1979**, *112*, 957.
3. Yamaguchi, M.; Hasabe, K.; Minami, T. *Tetrahedron Lett.* **1986**, *27*, 2401.
4. Despande, H. Y.; Khan, R. A.; Rai, B.; Ayyangar, N. R. *Synth. Commun.* **1993**, *23*, 2337.
5. All the new compounds reported in this paper have correct elemental analyses and spectral data.

**Compound 1:** Low melting white solid. Yield: 61%. IR (neat)  $\nu_{\text{C=O}}$  1714 cm<sup>-1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.8 (d, H-8, *J*=8.4 Hz), 7.75 (s, H-4), 7.36 (dd, H-7, *J*=8.1 and 7.5 Hz), 6.87 (d, H-6, *J*=7.5 Hz), 4.62 (m, H-2), 4.1 (s, -OMe, 3H), 4.00 (s, -OMe, 3H), 3.06 (m, -CH<sub>2</sub>, 2H), 1.51 (d, -CH<sub>3</sub>, 3H). <sup>13</sup>C NMR: 155.36 (C-10), 134–107 (aromatic carbons), 63.72 and 56.11 (two -OMe), 37.06 (-CH<sub>2</sub>), 21.14 (-CH<sub>3</sub>).

**Compound 2:** Mp 136–140°C. IR (CHCl<sub>3</sub>)  $\nu_{\text{C=O}}$  1708 cm<sup>-1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  7.71 (d, H-7, *J*=8.7 Hz), 7.13 (dd, H-6, *J*=6 Hz), 7.08 (d, H-5, *J*=5 Hz) 4.91 (m, H-2, 1H), 3.9 (s, -OMe, 3H), 3.04 (m, -CH<sub>2</sub>, 2H) 1.63 (d, -CH<sub>3</sub>, 3H). <sup>13</sup>C NMR: 157.88 (carbonyl), 124.63, 119.26, 105.11 (three aromatic protonated carbons), 76.95 (aliphatic -CH), 55.66 (-OMe), 30.51 (-CH<sub>2</sub>), 20.9 (-CH<sub>3</sub>)

6. Sibi, M. P.; Snieckus, V. *J. Org. Chem.* **1983**, *48*, 1835.
7. Sibi, M. P.; Chattopadhyaya, S.; Dankwardt, J. W.; Snieckus, V. *J. Am. Chem. Soc.* **1985**, *107*, 634.
8. Casas, R.; Cave, C.; d' Angelo, J. *Tetrahedron Lett.* **1995**, *36*, 1039.
9. Desvoye, M. L.; Demerseman, P.; Lechartier, J. P.; Pene, C.; Cheutin, A.; Royer, R. *Bull. Soc. Chim. Fr.* **1965**, 1443.